메뉴 건너뛰기




Volumn 21, Issue 11, 2007, Pages 1118-1126

LC-MS/MS determination of 2-(4-((2-(2S,5R)-2-Cyano-5-ethynyl-1- pyrrolidinyl)-2-oxoethylamino)-4-methyl-1-piperidinyl)-4- pyridinecarboxylic acid (ABT-279) in dog plasma with high-throughput protein precipitaion sample preparation

Author keywords

ABT 279; DPP IV inhibitor; High throughput; LC MS MS; Protein precipitation

Indexed keywords

DRUG PRODUCTS; MATRIX ALGEBRA; PRECIPITATION (CHEMICAL); QUALITY CONTROL; THROUGHPUT;

EID: 36749086987     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.855     Document Type: Article
Times cited : (4)

References (15)
  • 2
    • 9444285818 scopus 로고    scopus 로고
    • Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes
    • Ahren B, Gomis R, Standl E, Mills D and Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004a; 27: 2874-2880.
    • (2004) Diabetes Care , vol.27 , pp. 2874-2880
    • Ahren, B.1    Gomis, R.2    Standl, E.3    Mills, D.4    Schweizer, A.5
  • 4
    • 23044487247 scopus 로고    scopus 로고
    • Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year
    • Ahren B, Pacini G, Foley JE and Schweizer A. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 2005; 28: 1936-1940.
    • (2005) Diabetes Care , vol.28 , pp. 1936-1940
    • Ahren, B.1    Pacini, G.2    Foley, J.E.3    Schweizer, A.4
  • 5
    • 12244281855 scopus 로고    scopus 로고
    • Circulation and degradation of GIP and GLP-1
    • Deacon CF. Circulation and degradation of GIP and GLP-1. Hormone and Metabolic Research 2004; 36: 761-765.
    • (2004) Hormone and Metabolic Research , vol.36 , pp. 761-765
    • Deacon, C.F.1
  • 6
    • 0346753557 scopus 로고    scopus 로고
    • A strategy of plasma protein quantitation by selective reaction monitoring of an intact protein
    • Ji QC, Rodila R, Gage EM and El-Shourbagy TA. A strategy of plasma protein quantitation by selective reaction monitoring of an intact protein. Analytical Chemistry 2003; 75: 7008-7014.
    • (2003) Analytical Chemistry , vol.75 , pp. 7008-7014
    • Ji, Q.C.1    Rodila, R.2    Gage, E.M.3    El-Shourbagy, T.A.4
  • 7
    • 0029118049 scopus 로고
    • Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV
    • Kieffer TJ, McIntosh CH and Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995; 136: 3585-3596.
    • (1995) Endocrinology , vol.136 , pp. 3585-3596
    • Kieffer, T.J.1    McIntosh, C.H.2    Pederson, R.A.3
  • 8
    • 3843121153 scopus 로고    scopus 로고
    • Glucagon-like peptide-1: The basis of a new class of treatment for type 2 diabetes
    • Knudsen LB. Glucagon-like peptide-1: the basis of a new class of treatment for type 2 diabetes. Journal of Medicinal Chemistry 2004; 47: 4128-4134.
    • (2004) Journal of Medicinal Chemistry , vol.47 , pp. 4128-4134
    • Knudsen, L.B.1
  • 9
    • 85164048340 scopus 로고    scopus 로고
    • Madar DJ, Kopecka H, Pireh D, Yong H, Pei Z, Li X, Wiedeman PE, Djuric SW, Von Geldern TW, Fickes MG, Bhagavatula L, McDermott T, Wittenberger S, Richards SJ, Longenecker KL, Stewart KD, Lubben TH, Ballaron SJ, Stashko MA, Long MA, Wells H, Zinker BA, Mika AK, Beno DW, Kempf-Grote AJ, Polakowski J, Segreti J, Reinhart GA, Fryer RM, Sham HL and Trevillyan JM. Discovery of 2-(4-((2-(2S,5R)-2-Cyano-5-ethynyl-1- pyrrolidinyl)-2-oxoethylamino)-4-methyl-1-piperidinyl)-4- pyridinecarboxylic acid (ABT-279): a very potent, selective, e ffective, and well-tolerated inhibitor of dipeptidyl peptidase-IV, useful for the treatment of diabetes. Journal of Medicinal Chemistry 2006; 49: 6416-6420.
    • Madar DJ, Kopecka H, Pireh D, Yong H, Pei Z, Li X, Wiedeman PE, Djuric SW, Von Geldern TW, Fickes MG, Bhagavatula L, McDermott T, Wittenberger S, Richards SJ, Longenecker KL, Stewart KD, Lubben TH, Ballaron SJ, Stashko MA, Long MA, Wells H, Zinker BA, Mika AK, Beno DW, Kempf-Grote AJ, Polakowski J, Segreti J, Reinhart GA, Fryer RM, Sham HL and Trevillyan JM. Discovery of 2-(4-((2-(2S,5R)-2-Cyano-5-ethynyl-1- pyrrolidinyl)-2-oxoethylamino)-4-methyl-1-piperidinyl)-4- pyridinecarboxylic acid (ABT-279): a very potent, selective, e ffective, and well-tolerated inhibitor of dipeptidyl peptidase-IV, useful for the treatment of diabetes. Journal of Medicinal Chemistry 2006; 49: 6416-6420.
  • 10
    • 0027215348 scopus 로고
    • Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum
    • Mentlein R, Gallwitz B and Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. European Journal of Biochemistry 1993; 214: 829-835.
    • (1993) European Journal of Biochemistry , vol.214 , pp. 829-835
    • Mentlein, R.1    Gallwitz, B.2    Schmidt, W.E.3
  • 11
    • 0035857020 scopus 로고    scopus 로고
    • New drug targets for type 2 diabetes and the metabolic syndrome
    • Moller DE. New drug targets for type 2 diabetes and the metabolic syndrome. Nature 2001; 414: 821-827.
    • (2001) Nature , vol.414 , pp. 821-827
    • Moller, D.E.1
  • 12
    • 0026659679 scopus 로고
    • Glucagon-like peptide-1, a new hormone of the entero-insular axis
    • Orskov C. Glucagon-like peptide-1, a new hormone of the entero-insular axis. Diabetologia 1992: 35: 701-711.
    • (1992) Diabetologia , vol.35 , pp. 701-711
    • Orskov, C.1
  • 13
    • 0031033531 scopus 로고    scopus 로고
    • Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM
    • Rachman J, Barrow BA, Levy JC and Turner RC. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia 1997; 40: 205-211.
    • (1997) Diabetologia , vol.40 , pp. 205-211
    • Rachman, J.1    Barrow, B.A.2    Levy, J.C.3    Turner, R.C.4
  • 15
    • 33845565220 scopus 로고    scopus 로고
    • Developing multiple high-throughput GLP methods for an investigational drug candidate in various matrices within a 96-well plate
    • Zhang J, Kim EJ, Ji QC and El-Shourbagy TA. Developing multiple high-throughput GLP methods for an investigational drug candidate in various matrices within a 96-well plate. Rapid Communications in Mass Spectrometry 2006; 20: 3755-3760.
    • (2006) Rapid Communications in Mass Spectrometry , vol.20 , pp. 3755-3760
    • Zhang, J.1    Kim, E.J.2    Ji, Q.C.3    El-Shourbagy, T.A.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.